NU-6300

CAS No. 2070015-09-5

NU-6300 ( NU 6300;NU6300 )

Catalog No. M13220 CAS No. 2070015-09-5

NU-6300 is the first covalent, irreversible, ATP-Competitive CDK2 inhibitor with Ki of 6 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 312 Get Quote
50MG 1341 Get Quote
100MG 1791 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    NU-6300
  • Note
    Research use only, not for human use.
  • Brief Description
    NU-6300 is the first covalent, irreversible, ATP-Competitive CDK2 inhibitor with Ki of 6 nM.
  • Description
    NU-6300 is the first covalent, irreversible, ATP-Competitive CDK2 inhibitor with Ki of 6 nM; shows modest effect (GI50=8 uM) against human MCF-7 breast carcinoma cells; inhibits Rb phosphorylation in Rb-positive SKUT-1B cells.
  • Synonyms
    NU 6300;NU6300
  • Pathway
    Angiogenesis
  • Target
    CDK
  • Recptor
    CDK
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    2070015-09-5
  • Formula Weight
    413.49
  • Molecular Formula
    C20H23N5O3S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 32 mg/mL
  • SMILES
    O=S(C1=CC=C(NC2=NC(OCC3CCCCC3)=C4N=CNC4=N2)C=C1)(C=C)=O
  • Chemical Name
    6-(cyclohexylmethoxy)-N-(4-(vinylsulfonyl)phenyl)-9H-purin-2-amine

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Anscombe E, et al. Chem Biol. 2015 Sep 17;22(9):1159-64.
molnova catalog
related products
  • THZ1 2HCl

    THZ1 2HCl is a selective, covalent, and allosteric inhibitor of CDK7 with an IC50 of 3.2 nM. THZ1 2HCl has antiproliferative effects on a variety of cancer cell lines.

  • CDK4-IN-1

    CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM.

  • M2I-1

    The first small molecule Mad2 inhibitor that targets the binding of Mad2 to Cdc20; equally potent in inhibiting the binding of F-Mbp1 to Mad2.